论文部分内容阅读
目的检测癌-睾丸抗原(cancer-testis antigen,CTA)黑色素瘤抗原-A3(Melanoma antigen A3,MAGE-A3)蛋白在鼻咽癌(nasopharyngeal cancer,NPC)组织中的表达,为NPC诊断标记物及其肿瘤免疫治疗的可行性提供理论基础。方法用免疫组织化学法检测病理确诊的51例NPC组织和20例鼻咽部黏膜慢性炎症组织中MAGE-A3的表达情况,并将其表达结果与临床指标进行统计学分析。结果 MAGE-A3在NPC组织中的阳性表达率为64.71%(33/51);在鼻咽部黏膜慢性炎症组织中几乎不表达,只有2例呈弱阳性,两者之间差异有统计学意义(P<0.01);MAGE-A3表达与NPC患者的性别、年龄、疾病临床分期、有无淋巴结转移无明显相关性(P>0.05)。结论 MAGE-A3在NPC组织中呈较高表达,提示MAGE-A3有作为靶抗原的可能用于NPC免疫诊断和治疗。
Objective To detect the expression of cancer-testis antigen (CTA) Melanoma antigen A3 (MAGE-A3) in nasopharyngeal cancer (NPC) The feasibility of its tumor immunotherapy provides a theoretical basis. Methods Immunohistochemical method was used to detect the expression of MAGE-A3 in 51 pathologically confirmed NPC tissues and 20 nasopharyngeal mucosal chronic inflammatory tissues. The expression and clinical features of MAGE-A3 were analyzed. Results The positive expression rate of MAGE-A3 in NPC tissues was 64.71% (33/51). The expression of MAGE-A3 in nasopharyngeal mucosal chronic inflammatory tissues was almost not expressed, and only 2 cases were weakly positive, the difference between the two was statistically significant (P <0.01). There was no significant correlation between the expression of MAGE-A3 and the gender, age, clinical stage and lymph node metastasis of NPC patients (P> 0.05). Conclusion MAGE-A3 is highly expressed in NPC tissues, suggesting that MAGE-A3 may be used as a target antigen for immune diagnosis and treatment of NPC.